SLC5A2 and metabolic dysfunction-associated steatotic liver disease: The impetus for this systematic review and meta-analysis is to give a more precise estimate of effect and address variations with use of SGLT-2 inhibitors in the treatment of NAFLD to help guide clinical practice guideline development, with a renewed focus on the use of imaging and histopathology outcome measures as found in the up-to-date randomized controlled trials.